Enzalutamide versus abiraterone as a first-line endocrine...

BMC Cancer 2017 / 12 Vol. 17; Iss. 1

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial

Izumi, Kouji, Mizokami, Atsushi, Namiki, Mikio, Inoue, Shogo, Tanaka, Nobumichi, Yoshio, Yuko, Ishibashi, Kei, Kamiyama, Manabu, Kawai, Noriyasu, Enokida, Hideki, Shima, Takashi, Takahara, Shizuko
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
17
Language:
english
Journal:
BMC Cancer
DOI:
10.1186/s12885-017-3661-2
Date:
December, 2017
File:
PDF, 575 KB
english, 2017
Conversion to is in progress
Conversion to is failed